Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.
Theranostic programs are expanding rapidly, creating a growing need to understand how institutions implement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results